Karachi: Abbott Laboratories (Pakistan) Limited has announced a strong financial performance for the first quarter ended March 31, 2026, reporting a significant increase in profitability driven by higher sales and improved operating performance. The company’s Board of Directors approved the unaudited financial results during its meeting held on April 27, 2026.
The pharmaceutical company posted net sales of Rs. 17.705 billion during the January–March 2026 period, compared with Rs. 17.346 billion in the corresponding quarter of 2025. Growth in domestic sales helped offset a decline in export revenue, reflecting resilient demand in the local market.
Gross profit climbed to Rs. 6.698 billion, up from Rs. 5.842 billion a year earlier, supported by a lower cost of sales relative to revenue. Operating profit also strengthened, with profit before taxation reaching Rs. 3.291 billion, compared with Rs. 2.752 billion in the same period last year.
After accounting for taxation, Abbott Laboratories Pakistan reported a net profit of Rs. 1.940 billion, representing an increase of around 21% from Rs. 1.600 billion recorded in the first quarter of 2025. As a result, earnings per share (EPS) improved to Rs. 19.82, compared with Rs. 16.34 in the corresponding period last year.
The company’s financial position also remained solid. As of March 31, 2026, total assets stood at Rs. 50.169 billion, while shareholders’ equity increased to Rs. 33.687 billion, reflecting the impact of higher retained earnings generated during the quarter. Inventory levels rose to support business operations, while cash and bank balances remained healthy at Rs. 12.473 billion.
During the quarter, Abbott continued investing in its operations, spending on property, plant and equipment while maintaining a strong balance sheet. Although operating cash flow was impacted by higher tax payments and working capital movements, the company retained substantial liquidity to support future business activities.
The company stated that its complete quarterly report for the period ended March 31, 2026, would be transmitted separately through the PUCARS system within the prescribed timeline.
